LENZ Therapeutics Inc.

LENZ | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.08

+$0.01 (+0.25%)

At close: Sep 21, 2026, 4:00 PM ET

$4.08

$0 (0.00%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.25%

(1D)

Rating

Updated: Sep 12, 2026

37.5

Fundamentals Average

Market Sentiment Bearish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $127.93M

1D Range

4 4.13

52W Range

4 50.40

Valuation (TTM)

PE -1

PB 0.58

EV/EBITDA 0.73

Valuation (NTM)

Forward PE N/A

Forward PEG 0.03

Price Target $7

Cash Flow

FCF Yield -89.4%

SBC Adj. FCF Yield -98.5%

SBC Impact -10.2%

Margins

Gross Margin 90.1%

Operating Margin -631.7%

FCF Margin -532.8%

Growth (CAGR)

Revenue 3Y | 5Y 121.7% | 90.6%

Dil EPS 3Y | 5Y 52.1% | 32.7%

FCF 3Y | 5Y -25.7% | -8.3%

Returns

ROA -53.3%

ROE -53.4%

ROIC -61.8%

Financial Health

Net Cash

$220M

Current Ratio 13.55

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United Stat...

Sector Healthcare

Industry Biotechnology

Employees 152

IPO Date Jun 24, 2021

Website www.lenz-tx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 4, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+71.57%

Buy (4)

Hold (1)

Sell (0)

Analyst Details ➞